Insider Transactions in Q1 2021 at Staar Surgical CO (STAA)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 22
2021
|
James E Francese Sr. VP, Comm. Ops., NA, APAC |
SELL
Open market or private sale
|
Direct |
922
-1.72%
|
$88,512
$96.37 P/Share
|
|
Mar 22
2021
|
Samuel J Gesten Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,032
-2.37%
|
$99,072
$96.37 P/Share
|
|
Mar 22
2021
|
Jon K. Hayashida VP, Global Clinical, Medical |
SELL
Open market or private sale
|
Direct |
1,103
-10.22%
|
$105,888
$96.37 P/Share
|
|
Mar 16
2021
|
Scott D Barnes Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,664
-11.56%
|
$253,080
$95.0 P/Share
|
|
Mar 16
2021
|
Scott D Barnes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,664
+10.36%
|
$39,960
$15.25 P/Share
|
|
Mar 12
2021
|
James E Francese Sr. VP, Comm. Ops., NA, APAC |
BUY
Exercise of conversion of derivative security
|
Direct |
2,169
+3.89%
|
-
|
|
Mar 12
2021
|
Samuel J Gesten Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,430
+5.28%
|
-
|
|
Mar 12
2021
|
Keith Holliday Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,471
+7.25%
|
-
|
|
Mar 12
2021
|
Caren L Mason President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,363
+23.4%
|
-
|
|
Mar 12
2021
|
Patrick F. Williams Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,513
+7.03%
|
-
|
|
Mar 12
2021
|
Scott D Barnes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,936
+11.18%
|
-
|
|
Mar 11
2021
|
Scott D Barnes Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,665
-11.56%
|
$245,180
$92.0 P/Share
|
|
Mar 11
2021
|
Scott D Barnes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,665
+10.36%
|
$39,975
$15.25 P/Share
|
|
Mar 09
2021
|
Scott D Barnes Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
7,333
-14.21%
|
$645,304
$88.87 P/Share
|
|
Mar 09
2021
|
Scott D Barnes Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,333
+8.18%
|
$197,991
$27.31 P/Share
|
|
Mar 03
2021
|
Caren L Mason President & CEO |
SELL
Open market or private sale
|
Direct |
45,000
-50.55%
|
$4,410,000
$98.32 P/Share
|
|
Mar 03
2021
|
Caren L Mason President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+33.58%
|
$315,000
$7.76 P/Share
|
|
Mar 02
2021
|
Caren L Mason President & CEO |
SELL
Open market or private sale
|
Direct |
45,000
-50.55%
|
$4,635,000
$103.53 P/Share
|
|
Mar 02
2021
|
Caren L Mason President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+33.58%
|
$315,000
$7.76 P/Share
|
|
Mar 01
2021
|
Graydon C. Hansen Sr. VP, Global Operations |
SELL
Open market or private sale
|
Direct |
33,790
-33.63%
|
$3,514,160
$104.1 P/Share
|
|
Mar 01
2021
|
Graydon C. Hansen Sr. VP, Global Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
26,615
+8.36%
|
$638,760
$24.41 P/Share
|
|
Mar 01
2021
|
Jon K. Hayashida VP, Global Clinical, Medical |
SELL
Open market or private sale
|
Direct |
16,000
-59.71%
|
$1,680,000
$105.43 P/Share
|
|
Mar 01
2021
|
Jon K. Hayashida VP, Global Clinical, Medical |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+37.39%
|
$560,000
$35.98 P/Share
|
|
Mar 01
2021
|
Keith Holliday Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
18,991
-23.65%
|
$1,975,064
$104.33 P/Share
|
|
Mar 01
2021
|
Keith Holliday Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,783
+8.02%
|
$303,226
$22.81 P/Share
|
|
Mar 01
2021
|
Caren L Mason President & CEO |
SELL
Open market or private sale
|
Direct |
45,000
-50.55%
|
$4,680,000
$104.76 P/Share
|
|
Mar 01
2021
|
Caren L Mason President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
45,000
+33.58%
|
$315,000
$7.76 P/Share
|
|
Mar 01
2021
|
Lou Silverman Director |
SELL
Open market or private sale
|
Direct |
23,996
-91.89%
|
$2,495,584
$104.78 P/Share
|
|
Feb 12
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Feb 12
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
22,250
-0.23%
|
$2,759,000
$124.22 P/Share
|
|
Feb 11
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Feb 11
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
7,412
-0.08%
|
$919,088
$124.51 P/Share
|
|
Feb 10
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Feb 10
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
7,789
-0.08%
|
$965,836
$124.9 P/Share
|
|
Feb 09
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Feb 09
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
65,081
-0.67%
|
$8,070,044
$124.09 P/Share
|
|
Feb 08
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Feb 08
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
144,838
-1.48%
|
$17,670,236
$122.28 P/Share
|
|
Feb 05
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Feb 05
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
47,700
-0.48%
|
$5,533,200
$116.09 P/Share
|
|
Feb 04
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Feb 04
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
48,687
-0.49%
|
$5,404,257
$111.15 P/Share
|
|
Feb 03
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Feb 03
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
10,585
-0.11%
|
$1,164,350
$110.44 P/Share
|
|
Feb 02
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Feb 02
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,589
-0.02%
|
$174,790
$110.32 P/Share
|
|
Jan 28
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Jan 28
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
278,197
-2.73%
|
$29,210,685
$105.83 P/Share
|
|
Jan 27
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
0
|
-
|
|
Jan 27
2021
|
Broadwood Partners, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
164,686
-1.59%
|
$16,962,658
$103.99 P/Share
|